<p>The most common adverse reaction with Adalimumab was injection site reactions (erythema and/or itching, hemorrhage, pain or swelling). The most common adverse reactions leading to discontinuation of Adalimumab in rheumatoid arthritis were clinical flare reaction, rash and pneumonia.</p>

<ul>
	<li>Other adverse reactions of Adalimumab includes- Gastrointestinal disorders: Diverticulitis, large bowel perforations including perforations associated with diverticulitis and appendiceal perforations associated with appendicitis, pancreatitis.</li>
	<li>General disorders and administration site conditions: Pyrexia.</li>
	<li>Hepato-biliary disorders: Liver failure, hepatitis.</li>
	<li>Immune system disorders: Sarcoidosis.</li>
	<li>Neoplasms benign, malignant and unspecified (including cysts and polyps): Merkel Cell Carcinoma (neuroendocrine carcinoma of the skin).&nbsp;</li>
	<li>Nervous system disorders: Demyelinating disorders (e.g., optic neuritis, Guillain-Barr&eacute; syndrome).</li>
	<li>Cerebrovascular accident Respiratory disorders: Interstitial lung disease, including pulmonary fibrosis.</li>
	<li>Pulmonary embolism Skin reactions: Stevens Johnson Syndrome, cutaneous vasculitis, erythema multiforme, new or worsening psoriasis (all sub-types including pustular and palmoplantar), alopecia.</li>
	<li>Vascular disorders: Systemic vasculitis, deep vein thrombosis.</li>
</ul>